An Open Label Study of the Safety & Efficacy of Psilocybin in Participants

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04124341` - PCS in Severe Treatment Resistant Depression	N/A
Recruiting	`NCT03887715` - A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression	N/A
Completed	`NCT04727229` - Stellate Ganglion Block for Major Depressive Disorder.	Phase 4
Completed	`NCT04634669` - Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)	Phase 2
Withdrawn	`NCT03175887` - Investigational TMS Treatment for Depression	N/A
Completed	`NCT03134066` - Neurocognitive Features of Patients With Treatment-Resistant Depression
Active, not recruiting	`NCT01984710` - Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S	N/A
Completed	`NCT01935115` - Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy	Phase 4
Terminated	`NCT01687478` - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression	Phase 3
Completed	`NCT00531726` - Berlin Deep Brain Stimulation Depression Study	N/A
Recruiting	`NCT04041479` - Biomarker-guided rTMS for Treatment Resistant Depression	Phase 3
Recruiting	`NCT05870540` - BPL-003 Efficacy and Safety in Treatment Resistant Depression	Phase 2
Recruiting	`NCT04959253` - Psilocybin in Depression Resistant to Standard Treatments	Phase 2
Completed	`NCT04856124` - Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
Recruiting	`NCT03272698` - ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression	Phase 4
Active, not recruiting	`NCT04451135` - CET- REM (Correlating ECT Response to EEG Markers)	N/A
Recruiting	`NCT05680220` - 40 Hz Light Neurostimulation for Patients With Depression (FELIX)	N/A
Completed	`NCT03288675` - Stepped Care aiTBS 2 Depression Study (Ghent)	N/A
Recruiting	`NCT06138691` - KET-RO Plus RO DBT for Treatment Resistant Depression	Phase 1
Terminated	`NCT02675556` - Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression	Phase 1

NCT number	NCT04433858
Study type	Interventional
Source	Sheppard Pratt Health System
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 1, 2021
Completion date	October 24, 2023

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms